Without admitting wrongdoing, the company put a regulatory controversy to rest, but this was expensive. Cassava Sciences (SAVA -10.62%) ended the week with a piece of dispiriting news. It's going to reach deep into its coffers to settle charges brought by the most important financial-markets regulator governing its affairs. Many investors had enough of the company and sold off its stock to the point where it lost nearly 11% of its value across the Friday trading session. That was a far steeper fall than the ...